4th Quarter - Report — AMGEN, INC. for AMGEN INC (2012)

Firm

AMGEN, INC.

Client

AMGEN INC

Income

—

Expenses

$2,250,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Research and experimentation tax incentives and international tax issues, including: Administration's FY 2013 Revenue Proposals, Tax Reform, including House Ways and Means Discussion Draft and S. 2091, the United States Job Creation and International Tax Reform Act of 2012- S. 3521, the Family and Business Tax Cut Certainty Act of 2012 - H.R. 942, The American Research and Competitiveness Act of 2011

Lobbyist	Covered position, as disclosed
VICTORIA BLATTER	—
L NICOLE CURRIE	—
NANCY ELLEN MCCARTHY	Tax Counsel, Senate Finance Committee

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; Government Accountability Office (GAO); Medicare Payment Advisory Commission (MedPAC); HOUSE OF REPRESENTATIVES

Bills named: S. 2091 (112th), H.R. 942 (112th), S. 3521 (112th)

Copyright/Patent/Trademark CPT

Implementation of PL 112-029, the America Invents Act Trans-Pacific Partnership 12 years of data exclusivity ITC (International Trade Commission) Issues H.R. 6621, a bill to make technical corrections to the America Invents Act

Lobbyist	Covered position, as disclosed
WILLIAM O'BRIEN	—
HELEN RHEE	—

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE; Government Accountability Office (GAO); Medicare Payment Advisory Commission (MedPAC)

Bills named: H.R. 6621 (112th)

Health Issues HCR

Implementation of Health Care Reform, P.L 111-148, The Patient Protection and Affordable Care Act (Biosimilars, Track and Trace) HR 5651, the Food and Drug Administration Reform Act (Prescription Drug User Fee Act Reauthorization) S 1387, the Food and Drug Administration Safety and Innovation Act (Prescription Drug User Fee Act Reauthorization)

Lobbyist	Covered position, as disclosed
MARA GUARDUCCI	—
WILLIAM O'BRIEN	—
HELEN RHEE	—

Contacted: SENATE; Medicare Payment Advisory Commission (MedPAC); HOUSE OF REPRESENTATIVES; Government Accountability Office (GAO); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 5651 (112th)

Medicare/Medicaid MMM

H.R. 8, American Taxpayer Relief Act of 2012 (end stage renal disease prospective payment system bundling issues) Medicare Part B Drug reimbursement issues

Lobbyist	Covered position, as disclosed
VICTORIA BLATTER	—
CHAKA BURGESS	—
L NICOLE CURRIE	—
RUTH HOFFMAN	—
JESSE KERNS	—
CHRISTOPHER MANCILL	—
REBECCA MANDELL	—
HOWARD MOON	—
WILLIAM O'BRIEN	—
GREGORY PORTNER	—
HELEN RHEE	—

Contacted: Centers For Medicare and Medicaid Services (CMS); Medicare Payment Advisory Commission (MedPAC); Government Accountability Office (GAO); HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 8 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.